Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Limin Zhao, Xuefei Zhang, Huannan Guo, Mingyang Liu & Liming Wang. (2020) LOXL1-AS1 Contributes to Non-Small Cell Lung Cancer Progression by Regulating miR-3128/RHOXF2 Axis. OncoTargets and Therapy 13, pages 6063-6071.
Read now
Read now
Kiichiro Ninomiya & Katsuyuki Hotta. (2018) Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy 18:10, pages 1015-1021.
Read now
Read now
Articles from other publishers (20)
Masami Tsuchiya, Taku Obara, Masafumi Kikuchi & Nariyasu Mano. (2023) The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database. Cancer Chemotherapy and Pharmacology 91:6, pages 501-506.
Crossref
Crossref
Han Zhang, Hui Chen, Shutao Yin, Lihong Fan, Caiwei Jin, Chong Zhao & Hongbo Hu. (2023) Docosahexaenoic acid reverses PD-L1-mediated immune suppression by accelerating its ubiquitin-proteasome degradation. The Journal of Nutritional Biochemistry 112, pages 109186.
Crossref
Crossref
Irbaz B. Riaz, Mahnoor Islam, Ahsan Masood Khan, Syed Arsalan Ahmed Naqvi, Rabbia Siddiqi, Kaneez Zahra Rubab Khakwani, Noureen Asghar, Waleed Ikram, Syed A. Hussain, Parminder Singh, Jeremy L. Warner, Guru P. Sonpavde, Folakemi T. Odedina, Kenneth L. Kehl, Narjust Duma & Alan H. Bryce. (2022) Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials. The American Journal of Medicine 135:8, pages 984-992.e6.
Crossref
Crossref
Richard A. Lin, Jessica K. Lin & Shiaw‐Yih Lin. (2021) Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. The Kaohsiung Journal of Medical Sciences 37:6, pages 448-458.
Crossref
Crossref
Giacomo Pelizzari, Francesco Cortiula, Marco Giavarra, Michele Bartoletti, Camilla Lisanti, Vanessa Buoro, Monica Cattaneo, Ciro Rossetto, Simona Rizzato, Fabio Puglisi, Marianna Macerelli, Gianpiero Fasola & Alessandro Follador. (2020) Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs & Aging 37:9, pages 677-689.
Crossref
Crossref
Náthali Felícia Mineiro dos Santos Garrett, Ana Cristina Carvalho da Costa, Giovanni Damiani & Christiane Inocêncio Vasques. (2020) Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology 152, pages 102983.
Crossref
Crossref
Sabine Schmid, Jorune Suipyte, Christian Herrmann, Mohsen Mousavi, Felicitas Hitz & Martin Früh. (2020) Does progress achieved in the treatment of patients with metastatic non‐small‐cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. European Journal of Cancer Care 29:2.
Crossref
Crossref
Tamas Fulop, Jacek M. Witkowski, K. Hirokawa, A. Larbi & G. Pawelec. 2020. Geriatric Oncology. Geriatric Oncology
71
90
.
So-hyun Shim, Hee-jeong Seo, Hyung-bum Seo, Im-hak Cho, Chan Lee, So-yeon Kim, Chang-woo Han, Seong-ha Park, Young-ju Yun, In Lee, Jung-nam Kwon, Jin-woo Hong & Jun-yong Choi. (2019) Traditional Korean Medicine for Non-Small Cell Lung Cancer Patient Undergoing Pembrolizumab Immunotherapy: A Case Report. The Journal of Internal Korean Medicine 40:4, pages 709-722.
Crossref
Crossref
Fabio Perrotta, Danilo Rocco, Fabiana Vitiello, Raffaele De Palma, Germano Guerra, Antonio De Luca, Neal Navani & Andrea Bianco. (2019) Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients. International Journal of Molecular Sciences 20:9, pages 2258.
Crossref
Crossref
Joanne K. Gardner, Connie Jackaman, Cyril D. S. Mamotte & Delia J. Nelson. (2018) The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy. Frontiers in Medicine 5.
Crossref
Crossref
Marius Ilié, Mélanie Beaulande, Saima Ben Hadj, Emmanuel Chamorey, Renaud Schiappa, Elodie Long-Mira, Sandra Lassalle, Catherine Butori, Charlotte Cohen, Sylvie Leroy, Olivier Guérin, Jérôme Mouroux, Charles-Hugo Marquette, Jean-François Pomerol, Gilles Erb, Véronique Hofman & Paul Hofman. (2018) Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. Cancers 10:9, pages 326.
Crossref
Crossref
Francesco Grossi, Lucio Crinò, Antonio Logroscino, Stefania Canova, Angelo Delmonte, Barbara Melotti, Claudia Proto, Alain Gelibter, Federico Cappuzzo, Daniele Turci, Teresa Gamucci, Paola Antonelli, Paolo Marchetti, Armando Santoro, Sabrina Giusti, Francesco Di Costanzo, Lucio Giustini, Alessandro Del Conte, Lorenzo Livi, Diana Giannarelli & Filippo de Marinis. (2018) Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme. European Journal of Cancer 100, pages 126-134.
Crossref
Crossref
Eduard Teixidor, Elia Sais, Carmen Amalia Vásquez, Walter Carbajal, Alejandro Hernández, Gloria Sánchez, Angel Izquierdo, Sara Verdura, Javier A. Menéndez & Joaquim Bosch-Barrera. (2018) Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. Oncotarget 9:68, pages 33043-33049.
Crossref
Crossref
Flavia Radogna & Marc Diederich. (2018) Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy. Biochemical Pharmacology 153, pages 12-23.
Crossref
Crossref
Coraline Dumenil, Marie-Ange Massiani, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet & Etienne Giroux Leprieur. (2018) Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLOS ONE 13:4, pages e0195945.
Crossref
Crossref
Mark Owyong, Gizem Efe, Michael Owyong, Aamna J. Abbasi, Vaishnavi Sitarama & Vicki Plaks. (2018) Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix. Frontiers in Cell and Developmental Biology 6.
Crossref
Crossref
Tamas Fulop, J. M. Witkowski, K. Hirokawa, A. Larbi & G. Pawelec. 2018. Geriatric Oncology. Geriatric Oncology
1
20
.
Xiao-Ming Jiang, Yu-Lian Xu, Mu-Yang Huang, Le-Le Zhang, Min-Xia Su, Xiuping Chen & Jin-Jian Lu. (2017) Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacologica Sinica 38:11, pages 1512-1520.
Crossref
Crossref
Joanne K. Gardner, Cyril D.S. Mamotte, Connie Jackaman & Delia J. Nelson. (2017) Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules. Ageing Research Reviews 38, pages 40-51.
Crossref
Crossref